Clinical Trials Browser

Withdrawn × Nivolumab × Tumor-Agnostic × Clear all

NCT04315155 2020-10-28

BENEFIT

Phase 1 Withdrawn

Adenocarcinoma

NCT03652233 2019-06-20

Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 1 Withdrawn

Carcinoma, Squamous Cell